HLA-DRB111:01 has been linked to an increased risk of developing irAEs such as pruritus, while HLA-DQB103:01 has shown a nominally significant association with colitis in patients undergoing ICI therapy [ 32 - 35 ].
← all excerpts
From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events.
1
—
—